Search clinical trials for: NNC0143-0406

Total 182 results

Novo Nordisk A/S

Completed

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Spain, Hungary, Serbia, Bulgaria, Poland, Russian Federation, Latvia
Novo Nordisk A/S

Completed

Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Russian Federation, Germany
Novo Nordisk A/S

Terminated

An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)

Inflammation | Systemic Lupus Erythematosus

Serbia, Hungary, Poland, United States
Novo Nordisk A/S

Completed

A Randomised Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Inflammation | Crohn's Disease

United States, Spain, Bulgaria, Czech Republic, Poland, Slovakia
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0143-0406 A 0.6 mmol/L in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Austria
Novo Nordisk A/S

Completed

A Study Investigating the Distribution and Metabolism of Three 14C-labeled Radioactive Study Compounds

Type 2 Diabetes | Healthy Volunteers

Netherlands
CymaBay Therapeutics, Inc.

Completed

Study Investigating the Safety, Tolerability, and PK, PD, of CB-0406

Healthy Volunteers

Australia
Novo Nordisk A/S

Completed

First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.

Diabetes Mellitus, Type 2

United States
Novo Nordisk A/S

Active, not recruiting

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

Non-alcoholic Steatohepatitis

Spain, Denmark, Taiwan, Korea, Republic of, Australia, Canada, India, Singapore, United States, Turkey, Poland, Italy, Belgium, Puerto Rico, United Kingdom, Malaysia, Germany, Portugal, Bulgaria, Czechia, France, Greece, Japan, Russian...
Novo Nordisk A/S

Completed

A Research Study of a New Medicine NNC0113-6856 in Healthy Males

Type 2 Diabetes | Healthy Volunteers

Germany
Novo Nordisk A/S

Completed

Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of NNC0113-0987 in Healthy Male Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

United Kingdom
Janssen Research & Development, LLC

Completed

Efficacy of NNC0142-0002 in Subjects With Rheumatoid Arthritis (RA)

Inflammation | Rheumatoid Arthritis

Germany, Russian Federation, Ukraine
Janssen Research & Development, LLC

Completed

First-in-man Trial of NNC0142-0002 in Patients With Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Germany
Novo Nordisk A/S

Completed

Investigation on Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-0987 in an Oral Formulation in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

Diabetes | Diabetes Mellitus, Type 1

United States, Israel, Italy, Poland, Russian Federation, United Kingdom, Canada, Denmark, Sweden, Austria, Belgium, Spain, Ireland, Norway, Serbia, Finland, Portugal, Ukraine
Novo Nordisk A/S

Recruiting

Investigation of Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-6856 in Healthy Participants, Including a Subset of Healthy Japanese Participants

Healthy Participants

Germany
Novo Nordisk A/S

Completed

A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Completed

A Research Study Investigating NNC0247-0829 for Weight Management in People With Overweight or Obesity

Obesity | Overweight

United States
Novo Nordisk A/S

Completed

A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men

Non-alcoholic Steatohepatitis

Japan
Novo Nordisk A/S

Completed

A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity

Obesity | Overweight

United States
JW Pharmaceutical

Completed

Therapeutic Exploratory Study of CWP-0403

Type 2 Diabetes Mellitus

Korea, Republic of
Novo Nordisk A/S

Completed

A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese

Obesity | Overweight

United States
Novo Nordisk A/S

Completed

A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese

Overweight or Obesity | Metabolism and Nutrition Disorders

United States
Novo Nordisk A/S

Completed

A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese

Obesity and Overweight

United States
Novo Nordisk A/S

Completed

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects

Healthy | Diabetes

United Kingdom
Fougera Pharmaceuticals Inc.

Withdrawn

Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects

Atopic Dermatitis
Fougera Pharmaceuticals Inc.

Withdrawn

Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects

Atopic Dermatitis
Spirig Pharma Ltd.

Terminated

Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma

Nodular Basal Cell Carcinoma

Germany, Switzerland
Novo Nordisk A/S

Completed

Evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male Subjects

Healthy | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function

Obesity | Overweight

United States
Turning Point Therapeutics, Inc.

Terminated

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

Non Small Cell Lung Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Medullary Thyroid Cancer | RET Gene Mutation

United States, Korea, Republic of
Fougera Pharmaceuticals Inc.

Withdrawn

Study to Determine the Pharmacokinetics of Product 0405

Atopic Dermatitis
Vaxon Biotech

Completed

Safety Study of Vx006 Vaccine in Solid Tumor Patients

Solid Tumor

Greece
Kowa Research Institute, Inc.

Completed

A Multicenter, Open Label, Single Dose Study to Evaluate the Effect of Renal Insufficiency on the Pharmacokinetics of SK 0403

Type 2 Diabetes Mellitus

United States
Light Chain Bioscience - Novimmune SA

Completed

NI-0401 in Patients With Acute Renal Allograft Rejection

Acute Renal Transplant Rejection

France
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

Phase II Dose-Finding Study of SK-0403 With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Novo Nordisk A/S

Completed

A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations

Non-alcoholic Steatohepatitis

Canada
Novo Nordisk A/S

Completed

Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

A Research Study Looking Into Blood and Urine Levels of the Medicine NNC0194-0499 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function

Non-alcoholic Steatohepatitis (NASH)

Germany
Novo Nordisk A/S

Completed

A Research Study of How NNC0174-0833 Behaves in Chinese Volunteers Who Are Normal Weight, Overweight or With Obesity

Overweight and Obesity

China
iOmx Therapeutics AG

Recruiting

A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically

Solid Tumor

Spain
Blade Therapeutics

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Subjects

NASH - Nonalcoholic Steatohepatitis | Chronic Liver Disease

Australia
Novo Nordisk A/S

Completed

A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Terminated

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Inflammation | Rheumatoid Arthritis

United States, Mexico, France, Italy, Spain, Argentina, Belgium, Brazil, Czechia, Germany, Hungary, Poland, United Kingdom
Novo Nordisk A/S

Completed

First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects

Obesity | Metabolism and Nutrition Disorder

United States
Dana-Farber Cancer Institute

Completed

Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

Waldenstrom's Macroglobulinemia

United States
Valo Health, Inc.

Recruiting

Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy (Spectra)

Proliferative Diabetic Retinopathy | Non-proliferative Diabetic Retinopathy

United States

3

Subscribe